ArticleScientific reports2026
Identification of blood-brain barrier injury-related biomarkers in cerebral infarction using transcriptomic analysis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCerebral infarction leads to blood-brain barrier (BBB) disruption, exacerbating brain injury through edema, inflammation, and neuronal death. Although BBB damage is a critical event in stroke pathology, the underlying molecular mechanisms and reliable biomarkers remain poorly understood. This study aimed to identify key biomarkers associated with BBB injury following cerebral infarction using an in vitro model and transcriptomic approaches. Human cerebral microvascular endothelial cells (hCMEC/D3) were subjected to oxygen-glucose deprivation (OGD) and OGD/reoxygenation (OGD/R) to simulate ischemic and reperfusion injury. Cell viability, inflammatory cytokines, LDH release, and angiogenesis were assessed. Transcriptomic sequencing, weighted gene co-expression network analysis (WGCNA), and random forest algorithms were employed to identify differentially expressed genes and key biomarkers. OGD treatment significantly increased IL-1β, IL-6, TNF-α, and LDH levels, which were partially reversed by OGD/R. Transcriptomic analysis identified 1229 and 800 differentially expressed genes respectively in OGD and OGD/R comparisons. Enrichment analysis highlighted ribosome, endoplasmic reticulum, and mitochondrial pathways. Six core genes were screened, including RPS7, RPL36A, RPS9, RSL24D1, RPL41, and OSTC, all of which were upregulated under OGD and normalized after reoxygenation. We identified ribosome-related genes as potential biomarkers of BBB injury in cerebral infarction. These findings contribute to our understanding of BBB pathophysiology and suggest possible targets for future diagnostic and therapeutic development in ischemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.